Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China's CFDA Raises Fees for Drug Review

publication date: May 28, 2015
China's CFDA has sharply raised the fees it charges to review drugs and medical devices, a cost that drug companies are willing to pay if it means the agency will hire more reviewers and speed up the review process. The fee for a domestic innovative drug is now set at $100,637, a considerable jump from the $5,650 charged in 2013. At the end of 2014, the CFDA admitted that, despite numerous promises to shorten review times, the number of drugs awaiting approval had climbed to 18,500, up one-third over the year. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital